Prostatype Genomics is currently conducting a study of 160 patients together with seven leading Spanish hospitals and the Spanish National Association of Urology. The initial results are very strong and show that approximately 60% of patients would have been reclassified if Prostatype had been used for prognostic and treatment decisions after diagnosis. In a new retrospective multicentre study with Prostatype(R) in Spain including 160 patients from a total of seven hospitals, coordinated by the Spanish National association of Urology, an interim analysis has been performed after three hospitals completed the results.

The interim analysis shows that there is again strong evidence that Prostatype(R) provides important additional information that can change the treatment plan or actual treatment for prostate cancer patients initially classified as low or intermediate risk. The initial analysis indicates that the treatment plan can be changed in approximately as many as 60% of the cases if Prostatype(R) had been used after the established diagnosis. The study further indicates that Prostatype(R") can predict progression, i.e., the test can predict who needs curative treatment immediately upon diagnosis and who are not suitable for active monitoring.

The interim analysis also shows that Prostatype(R), confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer. In conclusion, the analysis shows that the patients who develop metastases and die due to prostate cancer are classified as high risk with Prostatype(R). at the time of diagnosis.